All adults 65 years or older should receive 1 dose of pneumococcal polysaccharide vaccine (PPSV23). In addition, CDC recommends PCV13 based on shared clinical decision-making for adults 65 years or older who do not have an immunocompromising condition†, cerebrospinal fluid leak, or cochlear implant.
For immunocompetent adult patients aged ≥65 years with CSF leak or cochlear implant, the CDC recommends a routine dose of Prevnar 13 (if not previously received) followed at least 8 weeks later by a routine dose of PNEUMOVAX 23.
If a patient needs both vaccines, you should administer PCV13 first, followed by PPSV23 at another visit. The interval between administrations depends on the age of the patient, the indication for giving it, and which vaccine you administer first.
ACIP recommends that both PCV13 and PPSV23 be given in series to adults aged ≥65 years. A dose of PCV13 should be given first followed by a dose of PPSV23 at least 1 year later to immunocompetent adults aged ≥65 years. The two vaccines should not be co-administered.
The main difference between Pneumovax 23 and Prevnar 13 is how many different types of bacteria they target. Pneumovax 23 protects against 23 types of pneumococcal bacteria and is used in adults, while Prevnar 13 protects against 13 types of pneumococcal bacteria, and was designed primarily for children.
Funded pneumococcal vaccines for children and adults with an eligible condition listed on the previous page are: » Prevenar 13 » Replaces Synflorix doses on the routine Immunisation Schedule once the high-risk condition has been identified, OR » One dose if aged 18 months to under 18 years, and have previously received
Yes. People with HIV infection are at high risk of pneumococcal disease. They should receive both PCV13 and PPSV23 vaccines as soon as possible after diagnosis. They should first be given PCV13, followed by PPSV23 at least 8 weeks later.
The pneumococcal vaccine is given as a single injection in adults. The vaccine is injected as a liquid solution of 0.5 mL into the muscle ( intramuscular or IM ), typically deltoid muscle, or under the skin (subcutaneous or SC).
PPSV23 covers a greater number of pneumococcal serotypes but may not induce effective or lasting immunity. PCV13 seems to produce greater potential for immune memory.
Pneumovax 23 (Pneumovax 23 coupons | What is Pneumovax 23?) is also known as pneumococcal vaccine polyvalent injection (or PPSV23 vaccine)—it protects against 23 types of pneumococcal bacteria.
Prevnar 13 protects against 13 different pneumococcal serotypes. Prevnar 20 contains 7 additional serotypes compared to Prevnar 13. In a recent press release, Pfizer stated that the 20 serotypes contained in Prevnar 20 cause more than 50% of invasive pneumococcal disease cases in older adults.
To prevent pneumococcal disease, there are two types of pneumococcal vaccines: the pneumococcal polysaccharide vaccine (PPSV23) and the pneumococcal conjugate vaccine (PCV13).
PCV13 vaccination is no longer routinely recommended for all adults age >65 years. Instead, shared clinical decision-making for PCV13 use is recommended for persons age >65 years who do not have an immunocompromising condition, CSF leak, or cochlear implant and who have not previously received PCV13.
PNEUMOVAX 23 is recommended by the CDC for people 65 years or older — even if they may have already received a dose of another vaccine for pneumococcal disease. It is also recommended for adults 19 to 64 years of age who have certain chronic conditions (diabetes, heart disease, or COPD).
Prevnar 13 shot may no longer be necessary for healthy adults over 65. En español | While pneumococcal disease is often mild, it can sometimes have serious and even deadly repercussions for those 65 years or older — particularly when the bacteria that causes it invade the lungs, causing pneumonia.